Kymera Therapeutics Inc
Ownership
Ownership Structure
Who owns Kymera Therapeutics Inc (KYMR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 79.4% of the shares are freely tradable; institutional investors hold 117.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.85 | 12,349,256 | +5.5 | 06/30/2026 |
| Baker Bros Advisors LP | 10.41 | 8,657,242 | +0.0 | 06/30/2026 |
| venBio Select Advisor LLC | 8.99 | 7,474,747 | +0.0 | 06/30/2026 |
| T. Rowe Price Associates, Inc. | 8.55 | 7,112,980 | +17.4 | 06/30/2026 |
| T. Rowe Price Investment Management,Inc. | 7.53 | 6,257,261 | +14.5 | 06/30/2026 |
| BlackRock Inc | 6.66 | 5,538,210 | +9.4 | 06/30/2026 |
| Bvf Inc | 4.66 | 3,872,052 | -29.6 | 06/30/2026 |
| Wellington Management Company LLP | 4.42 | 3,675,028 | -5.5 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 3.60 | 2,992,193 | +4.1 | 06/30/2026 |
| Siren, L.L.C. | 3.53 | 2,935,830 | -7.9 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Mainolfi Nello | Chief Executive Officer | 666,568 | 84,387,509 $ | Oct 1, 2026 | direct |
| Adams Brian | Chief Legal Officer | 50,254 | 6,362,156 $ | Sep 4, 2026 | direct |
| Rooney Terence | Chief Medical Officer | 38,000 | 4,810,800 $ | Jul 27, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 262 | 116.12 | 30,423 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 8,230 | 115.40 | 949,742 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 7,601 | 114.43 | 869,782 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 4,876 | 113.24 | 552,158 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 5,506 | 112.42 | 618,985 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 3,525 | 111.44 | 392,826 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer | Other | 30,000 | 2.08 | 62,400 |
| Sep 4, 2026 | Adams Brian | Chief Legal Officer | Sell | 2,137 | 117.57 | 251,247 |
| Sep 4, 2026 | Adams Brian | Chief Legal Officer | Sell | 3,025 | 116.81 | 353,350 |
| Sep 4, 2026 | Adams Brian | Chief Legal Officer | Sell | 1,209 | 115.55 | 139,700 |
| Jul 27, 2026 | Rooney Terence | Chief Medical Officer | Other | 38,000 | 0.00 | – |
| Apr 22, 2026 | Bruce Booth | Director | Sell | 5,900 | 89.96 | 530,764 |
| Apr 22, 2026 | Bruce Booth | Director | Sell | 100 | 90.08 | 9,008 |
| Apr 22, 2026 | Jeremy G Chadwick | COO | Sell | 300 | 90.00 | 27,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.